10-Q: Protagonist Therapeutics Q3 Loss Amid R&D Expansion

Protagonist Therapeutics reported a net loss of $39.3 million for Q3 2025, driven by increased R&D spending on new drug candidates, while advancing its Phase 3 programs for icotrokinra and rusfertide.

Summary

• A net loss of $39.3 million was reported for the three months ended September 30, 2025, compared to a net loss of $33.2 million for the same period in 2024.
• A net loss of $85.8 million was reported for the nine months ended September 30, 2025, a significant reversal from net income of $143.5 million for the same period in 2024.
• License and collaboration revenue for the nine months ended September 30, 2025, decreased by 85% to $38.6 million from $263.8 million in the prior year, primarily due to the timing of large upfront payments and milestones recognized in 2024.
• Research and development expenses increased by 11% to $40.0 million for Q3 2025 and by 9% to $112.9 million for the nine months ended September 30, 2025, driven by investment in new drug candidates PN-881 and PN-477.
• An NDA for icotrokinra was submitted to the U.S. FDA in July 2025 and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in September 2025 for moderate-to-severe plaque psoriasis.
• Rusfertide was granted Breakthrough Therapy designation by the FDA in August 2025 for the treatment of erythrocytosis in patients with polycythemia vera (PV), with an NDA filing expected by the end of 2025.
• Positive topline results were announced from the ANTHEM-UC Phase 2b trial for icotrokinra in adults with moderately-to-severely active ulcerative colitis, meeting its primary endpoint.
• The first human subject was dosed in the Phase 1 clinical trial for PN-881, an IL-17 oral peptide antagonist, in October 2025.
• PN-477, an obesity triple agonist peptide, was selected as a development candidate, with Phase 1 clinical studies anticipated by mid-2026 (subcutaneous) and the second half of 2026 (oral).
• Cash, cash equivalents, and marketable securities totaled $678.8 million as of September 30, 2025, up from $559.2 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: While financial results show a significant loss and revenue decrease compared to the prior year, this is largely due to the timing of large collaboration payments in 2024. The company has made substantial progress in its clinical pipeline with multiple NDA/MAA submissions, Breakthrough Therapy designation, and positive Phase 2/3 trial results, indicating strong underlying scientific and clinical momentum. The increased R&D spend on new candidates also points to future growth potential. However, the financial performance is currently negative, and macroeconomic and regulatory risks are noted.

Positives

• Icotrokinra NDA submitted to the U.S. FDA in July 2025 and MAA to the EMA in September 2025 for moderate-to-severe plaque psoriasis, indicating significant progress towards commercialization.
• Icotrokinra met all primary and co-primary endpoints across four pivotal Phase 3 ICONIC trials, demonstrating significant skin clearance and a favorable safety profile in plaque psoriasis.
• ICONIC-ADVANCE 1 & 2 trials showed icotrokinra achieved superiority to deucravacitinib in moderate-to-severe plaque psoriasis, highlighting a competitive advantage.
• Positive topline results from the ANTHEM-UC Phase 2b trial for icotrokinra in ulcerative colitis, meeting the primary endpoint of clinical response in all dose groups and demonstrating clinically meaningful differences in key secondary endpoints.
• Rusfertide granted Breakthrough Therapy designation by the FDA in August 2025 for erythrocytosis in patients with PV, which may expedite its development and review.
• The Phase 3 VERIFY trial for rusfertide in PV met its primary endpoint, with 76.9% of patients achieving a clinical response compared to 32.9% in the placebo group (p<0.0001).
• Rusfertide also showed statistically significant improvements in patient-reported outcomes of fatigue and symptom burden in PV patients, being the first investigational therapy to demonstrate this.
• The first human subject was dosed in the Phase 1 clinical trial for PN-881, an IL-17 oral peptide antagonist, in October 2025, expanding the early-stage pipeline.
• PN-477, an obesity triple agonist peptide, was selected as a development candidate, with IND-enabling studies underway, indicating growth in the metabolic disease area.
• A strong cash position of $678.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, provides liquidity for at least the next twelve months.

Negatives

• A net loss of $39.3 million was reported for the three months ended September 30, 2025, an 18% increase from the $33.2 million net loss in Q3 2024.
• A net loss of $85.8 million was reported for the nine months ended September 30, 2025, a significant reversal from the net income of $143.5 million in the prior year period.
• License and collaboration revenue for the nine months ended September 30, 2025, decreased by 85% to $38.6 million from $263.8 million in the prior year, primarily due to the non-recurrence of large upfront payments and milestones from 2024.
• Revenue in 2025 is expected to reduce significantly compared to 2024, which will also impact net income.
• Interest income decreased by 8% for the three months ended September 30, 2025, due to lower invested balances.
• An accumulated deficit of $426.3 million has been incurred from inception through September 30, 2025.

Risks

• Disruptions at the FDA and other government agencies, including government shutdowns (such as the one commenced in October 2025), workforce reductions, or policy changes, could significantly impact the timely review and processing of regulatory submissions, materially affecting the business.
• Unstable market and macroeconomic conditions, including elevated and sustained inflation, changes in tariffs or trade policy, geopolitical instability (e.g., Ukraine/Russia, Middle East, China/Taiwan tensions), and high interest rates, may adversely affect the business, financial condition, and stock price.
• Inflationary factors, such as increases in the cost of clinical supplies, interest rates, overhead costs, and transportation costs, may adversely affect operating results.
• The imposition of new U.S. tariffs (up to 100%) on imported branded or patented pharmaceuticals could increase manufacturing costs for product candidates and lead to delays in initiating trials.
• Deterioration in credit and financial markets could make necessary debt or equity financing more difficult, costly, and dilutive.
• There is a risk that one or more current service providers, manufacturers, and other partners may not survive difficult economic times, which could directly affect the ability to attain operating goals.
• The stock price has been and will likely continue to be volatile and may decline regardless of operating performance.
• Expect to incur additional losses in the future as development continues and investments are made in pre-clinical discovery programs.
• Inability to fully estimate the duration and completion costs of research and development projects or when and to what extent revenue will be generated from the commercialization and sale of any product candidates.

Future Outlook

The company expects to incur additional losses in the future as it continues rusfertide Phase 3 development activities through a potential NDA filing and invests in its pre-clinical discovery programs. Research and development expenses are anticipated to increase in the near term due to preparations for regulatory filings and commercialization for rusfertide, and the advancement of PN-881 and PN-477. Revenue in 2025 is expected to significantly decrease compared to 2024, which will impact net income, primarily due to the timing of large collaboration payments in the prior year. An NDA filing for rusfertide in PV is expected by the end of 2025. Phase 1 clinical studies for PN-477 (subcutaneous) are anticipated by mid-2026, and for PN-477 (oral) in the second half of 2026. A development candidate for an orally administered hepcidin mimetic or ferroportin inhibitor is expected to be nominated by the end of 2025. Existing cash, cash equivalents, and marketable securities are projected to fund operations for at least the next twelve months.

Management Comments

• "We expect to continue to incur significant research and development expenses, and other expenses related to our ongoing operations, product development, pre-clinical discovery programs and pre-commercialization activities."
• "As a result, we may incur losses in the future as we continue the development of, and seek regulatory approval for, our product candidates."
• "Our revenue for the year ended December 31, 2025 is expected to be comprised of (i) proportional recognition of the $30.6 million recorded in deferred revenue as of December 31, 2024 and (ii) the recognition of additional milestones achieved during the year, which are expected to be substantially lower than in 2024. Accordingly, revenue in 2025 is expected to reduce significantly, which will also impact our net income."
• "We expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months from the date of this Quarterly Report based on current operating plans and financial forecasts."

Industry Context

The company operates in the highly competitive biopharmaceutical sector, focusing on peptide therapeutics for inflammatory/immunomodulatory diseases and hematology/blood disorders. Icotrokinra, an oral IL-23R antagonist, aims to compete with established injectable antibody drugs, potentially offering increased convenience and compliance for plaque psoriasis and ulcerative colitis. Its demonstrated superiority to deucravacitinib in some trials positions it favorably against other oral therapies. Rusfertide, a hepcidin mimetic, targets the rare blood disorder polycythemia vera, a niche market with high unmet medical need, underscored by its Breakthrough Therapy designation. The expansion into new therapeutic areas with PN-881 (IL-17 antagonist) for immune-mediated skin diseases and PN-477 (obesity triple agonist) for metabolic diseases reflects a broader industry trend towards diversifying pipelines and developing oral alternatives to injectable biologics, leveraging proprietary peptide discovery platforms for differentiated drug delivery.

Comparison to Industry Standards

• Icotrokinra demonstrated superiority to deucravacitinib, an oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis in the ICONIC-ADVANCE 1 & 2 trials, indicating a strong competitive profile against an existing oral therapy.
• The ICONIC-ASCEND trial for icotrokinra is noted as the "first-ever head-to-head study seeking to demonstrate the superiority of an oral pill compared to an injectable biologic (ustekinumab)" in psoriasis, setting a high benchmark for comparative efficacy against a leading injectable biologic.
• Rusfertide is the "first investigational therapy to prospectively demonstrate a statistically significant improvement in these patient-reported outcomes of fatigue and symptom burden in patients with PV," suggesting a potential best-in-class or first-in-class profile for improving quality of life in polycythemia vera patients.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceeding that could have a material adverse effect on the business, operating results, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Potential for dilution if additional capital is raised through equity offerings; continued stock price volatility; potential for long-term value creation from successful drug development and commercialization.
• Employees: Continued investment in R&D and pipeline expansion suggests stable or growing employment opportunities in research and development roles; stock-based compensation remains a significant component of overall compensation.
• Patients: Potential for new and improved treatment options for moderate-to-severe plaque psoriasis, ulcerative colitis, and polycythemia vera, as well as future therapies for immune-mediated skin diseases and obesity.
• Collaboration Partners (Janssen, Takeda): Continued collaboration and potential for future milestone payments and royalties based on regulatory approvals and commercial success.
• Creditors: A strong cash position reduces immediate concerns, but future debt financing could introduce restrictive covenants.

Next Steps

• Seek FDA approval of icotrokinra NDA in any indication (potential $50.0 million milestone).
• Seek acceptance of icotrokinra NDA for a second indication (potential $25.0 million milestone).
• Seek FDA approval of icotrokinra NDA for a second indication (potential $45.0 million milestone).
• Seek acceptance of icotrokinra NDA for a third indication (potential $35.0 million milestone).
• Seek FDA approval of icotrokinra NDA for a third indication (potential $50.0 million milestone).
• Submit NDA filing for rusfertide in PV by the end of 2025.
• Seek FDA approval of rusfertide NDA in PV (potential $50.0 million or $75.0 million milestone).
• Seek first regulatory approval for rusfertide in PV in three European countries, after pricing and reimbursement approval (potential $15.0 million milestone).
• Seek first regulatory approval for rusfertide in PV in Japan (potential $10.0 million milestone).
• Present clinical data on rusfertide in PV, including durability of response and safety results through Week 52 from the VERIFY trial, at the 67th Annual American Society of Hematology (ASH) Annual Meeting in December 2025.
• Utilize results of the PN-881 Phase 1 study to inform the design and dosing in a subsequent dose-ranging psoriasis trial.
• Pursue rapid expansion of PN-881 into other IL-17 mediated diseases based on results observed in psoriasis studies.
• Continue IND-enabling studies of PN-477.
• Initiate Phase 1 clinical studies for PN-477 (subcutaneous) anticipated by mid-2026.
• Initiate Phase 1 clinical studies for PN-477 (oral) anticipated in the second half of 2026.
• Nominate a development candidate for an orally administered hepcidin mimetic or ferroportin inhibitor by the end of 2025.
• Evaluate the potential impact of the One Big Beautiful Bill Act on consolidated financial statements.

Key Dates

Recommendation

While the company reported a significant net loss and revenue decrease compared to the prior year, this is largely attributable to the timing of substantial collaboration payments in 2024. Operationally, Protagonist Therapeutics has demonstrated strong progress with multiple regulatory submissions (icotrokinra NDA/MAA), a Breakthrough Therapy designation (rusfertide), and positive Phase 2/3 clinical trial results across its pipeline. The increased R&D investment in new candidates (PN-881, PN-477) indicates a robust long-term growth strategy. However, the company is still in a development phase, incurring losses, and faces macroeconomic and regulatory risks. The current financial performance is a step back from 2024's income, but the clinical advancements provide a solid foundation. Investors should hold to monitor the outcomes of regulatory approvals and the progression of early-stage pipeline assets.

Keywords

biopharmaceutical, peptide therapeutics, icotrokinra, rusfertide, plaque psoriasis, polycythemia vera, ulcerative colitis, IL-23R antagonist, hepcidin mimetic, PN-881, IL-17 antagonist, PN-477, GLP-1 agonist, GIP agonist, GCG agonist, Phase 3 clinical trials, NDA submission, MAA submission, Breakthrough Therapy designation, drug discovery, clinical development, Janssen, Takeda, financial results, biotech, pharmaceuticals, regulatory approval, drug development, rare diseases, autoimmune diseases, metabolic diseases, obesity